Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 3Stomach Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Prostatic Neoplasms 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Muscular Atrophy 1Mouth Neoplasms 1Lymphoma, Follicular 1Liver Neoplasms 1Hemorrhage 1Hematologic Neoplasms 1Glioblastoma 1Gallbladder Neoplasms 1Colonic Neoplasms 1Child Nutrition Disorders 1COVID-19 1

Interventions

Gemcitabine 5Cisplatin 5Oxaliplatin 2pertuzumab 1durvalumab 1Trastuzumab 1Standard of Care 1Radiotherapy, Intensity-Modulated 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Lymph Node Excision 1Laparoscopy 1Geriatric Assessment 1Everolimus 1Drug Therapy 1Chemoradiotherapy 1Capecitabine 1ARRY-334543 1130-nm albumin-bound paclitaxel 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Gallbladder Neoplasms × Standard of Care × Clear all
NCT05833815 2024-08-13

Addition of Everolimus to Standard of Care in Carcinoma Gallbladder

Banaras Hindu University

Phase 2/3 Recruiting
56 enrolled
Gastrointestinal

Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡